Prescribing Clinical Network

<table>
<thead>
<tr>
<th>Policy Statement</th>
<th>Riluzole for the treatment of Motor Neurone Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy No:</td>
<td>PCN 360 - 2018</td>
</tr>
<tr>
<td>Date of Issue</td>
<td>September 2018</td>
</tr>
<tr>
<td>Review Date:</td>
<td>September 2021&lt;br&gt;(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</td>
</tr>
</tbody>
</table>

**Recommendations:**
The Prescribing Clinical Network recommends the use of riluzole in line with NICE TA 20, for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease.

Riluzole should be only be initiated by a neurological specialist with expertise in the management of MND, but can be managed in primary care via a shared care agreement with general practitioners, and as such is considered as AMBER on the traffic light system.

Riluzole is excluded from the National Tariff when administered for its licensed indication. Providers should apply for funding using the Blueteq system at initiation of treatment.

**Key Considerations:**
- Generic riluzole has been considered by the PCN and has been assigned an AMBER traffic light status.
- NOTE: the branded product, Rilutek, was considered BLACK at the PCN In May 2017.
- This is a review of the PCN recommendation made in April 2008

**Date taken to Prescribing Clinical Network**<br>5th September 2018

**Agreed by PCN members**<br>18th September 2018

*Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG*